Ian Odell, MD, PhD

Ian Odell, MD, PhD

Ian Odell, MD, PhD

Assistant Professor

Dermatology Director, Adult Primary Care Center

Scleroderma and Myositis Program

Yale University School of Medicine

Related Videos

Given the multiple clinical phenotypes and subtypes that are observed with systemic sclerosis, what therapeutic approaches are aligned with what forms of the disease? And what is the evidence-based role for ECP? Video

Given the multiple clinical phenotypes and subtypes that are observed with systemic sclerosis, what therapeutic approaches are aligned with what forms of the disease? And what is the evidence-based role for ECP?

Since you and others at Yale have treated a number of patients with scleroderma—and other conditions—with ECP, can you share your real world clinical experience with this treatment modality? And how measure clinical response to this therapy? Video

Since you and others at Yale have treated a number of patients with scleroderma—and other conditions—with ECP, can you share your real world clinical experience with this treatment modality? And how measure clinical response to this therapy?

Based on clinical trial data, the benefit-to-risk equation, contraindications, and experience with ECP at your institution, which patients with scleroderma are you treating with ECP, and what strategies are you deploying to optimize outcomes? Video

Based on clinical trial data, the benefit-to-risk equation, contraindications, and experience with ECP at your institution, which patients with scleroderma are you treating with ECP, and what strategies are you deploying to optimize outcomes?

Can you provide a brief review of scleroderma—systemic sclerosis—as a multisystem connective tissue disease characterized by humoral and cellular immune abnormalities and fibroblast activation? Video

Can you provide a brief review of scleroderma—systemic sclerosis—as a multisystem connective tissue disease characterized by humoral and cellular immune abnormalities and fibroblast activation?

What findings of progressive skin involvement with scleroderma are clinical triggers to warrant consideration of ECP in the heterogeneous population of patients? What is the clinical trial data supporting the use of ECP in scleroderma? Video

What findings of progressive skin involvement with scleroderma are clinical triggers to warrant consideration of ECP in the heterogeneous population of patients? What is the clinical trial data supporting the use of ECP in scleroderma?

What is the schedule—i.e. frequency of ECP treatments—that patients with scleroderma require, and what are the possible side effects that require monitoring? Video

What is the schedule—i.e. frequency of ECP treatments—that patients with scleroderma require, and what are the possible side effects that require monitoring?